Figure 6 | Blood Cancer Journal

Figure 6

From: Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice

Figure 6

Improved survival and suppression of the growth of HTLV-1-infected T cells by 17-DMAG oral treatment. (a) Kaplan–Meier survival curve of HTLV-1-infected huNOG mice. All mice have reconstituted human immune system by the transplantation of hematopoietic stem cells (huNOG) and have received 1 million JEX cells, which produce HTVL-1 infectious virus (see the details in Supplementary Figure 4). JEX/huNOG mice received 17-DMAG by oral administration for 4 weeks (2–6 weeks post inoculation, five times/week) at the dosage of 25 mg/kg (orange line) and 15 mg/kg (pink line). Control mice received the same volume of PBS. (b) The percentage of CD25-positive T cells, PVL and the number of HTLV-1-infected cells in peripheral blood of infected mice are shown. Upper panel represents the results from 17-DMAG-treated (25 mg/kg) mice; lower panel represents those of control mice. (c) Same experiments with 17-DMAG (15 mg/kg, upper panel) and PBS control (lower panel). PBS, phosphate buffered saline; PVL, proviral load.

Back to article page